社区中具有代谢和酒精风险因素人群的脂肪性肝病患病率、严重程度及决定因素
在2017年10月至2022年11月期间招募3123名30-75岁具有代谢和/或酒精风险的社区人群,70%诊断为脂肪性肝病(SLD),其中MASLD占51%、MetALD占13%、ALD占6.3%。10%有肝脏硬度升高,2%经活检证实为晚期肝纤维化。ALD亚类的肝脏疾病严重程度最高。
要点
- 在具有代谢和/或酒精风险的社区人群中,SLD患病率为70%。
- MASLD、MetALD和ALD分别占51%、13%和6.3%。
- ALD亚类的肝脏疾病严重程度最高,LSM≥8 kPa者占25%,活检证实的晚期纤维化占8%。
核心结论
- 在具有心血管代谢和/或酒精风险因素的个体中,70%患有SLD,10%有肝脏硬度升高,2%经活检证实为晚期肝纤维化。
研究设计与样本
- 2017年10月至2022年11月期间招募30-75岁市民,1:1纳入代谢队列(BMI>30 kg/m2和/或2型糖尿病且无长期酒精摄入增加)或酒精队列( ongoing/prior increased alcohol consumption),共纳入3123名参与者,代谢队列1599人,酒精队列1524人。
- 采用受控衰减参数(CAP)评估肝脂肪变,肝脏硬度测量(LSM)评估肝纤维化,对LSM≥8 kPa的参与者进行肝活检。
主要发现
- 共2197人(70%)诊断为SLD:1603人(51%)为MASLD,398人(13%)为MetALD,196人(6.3%)为ALD。
- 307人(9.8%)LSM≥8 kPa,其中169人(55%)接受了肝活检。
- 代谢队列中,1237人(77%)有SLD,147人(9.2%)LSM≥8 kPa,24人(1.5%)活检证实为晚期肝纤维化。
- 酒精队列中,960人(63%)有SLD,160人(10.5%)LSM≥8 kPa,46人(3.1%)活检证实为晚期肝纤维化。
- 各亚类中,ALD的肝脏疾病严重程度最高(LSM≥8 kPa:25%;活检证实的晚期纤维化:8%),MASLD与MetALD的严重程度相当(LSM≥8 kPa:12%,活检证实的晚期纤维化:3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出方法学局限性包括横断面设计和有限的普遍性,在解释结果时应予以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Individuals with steatotic liver disease (SLD) are affected by metabolic dysfunction and/or high alcohol consumption; however, the prevalence of SLD in at-risk individuals remains underexplored. We aimed to investigate the prevalence and severity of SLD and its subclasses: metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic- and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD) in at-risk individuals. METHODS: Between Oct 2017 and Nov 2022, citizens aged 30-75 years were recruited 1:1 into: a) the metabolic cohort, comprising individuals with BMI >30 kg/m2 and/or type 2 diabetes without prolonged increased alcohol consumption; or b) the alcohol cohort, comprising individuals with ongoing/prior increased alcohol consumption. We assessed liver steatosis by controlled attenuation parameter (CAP), liver fibrosis by liver stiffness measurements (LSM) and performed liver biopsies in participants with LSM ≥8 kPa. RESULTS: We included 3,123 participants; 1,599 in the metabolic cohort and 1,524 in the alcohol cohort. In total, 2,197 (70%) were diagnosed with SLD: 1,603 (51%) with MASLD, 398 (13%) with MetALD, and 196 (6.3%) with ALD. Of 307 (9.8%) with LSM ≥8 kPa, 169 underwent liver biopsy (55%). In the metabolic cohort, 1,237 (77%) had SLD, 147 (9.2%) had LSM ≥8 kPa, and 24 (1.5%) had biopsy-confirmed advanced liver fibrosis. In the alcohol cohort, 960 (63%) had SLD, 160 (10.5%) had LSM ≥8 kPa, and 46 (3.1%) had biopsy-confirmed advanced liver fibrosis. Across subclasses, ALD demonstrated the highest liver disease severity (LSM ≥8 kPa: 25%; biopsy-confirmed advanced fibrosis: 8%), and severity was comparable between MASLD and MetALD (LSM ≥8 kPa: 12%, biopsy-confirmed advanced fibrosis: 3%). CONCLUSIONS: Among individuals with cardiometabolic and/or alcohol risk factors, 70% had SLD, 10% had elevated liver stiffness, and 2% had biopsy-confirmed advanced liver fibrosis. IMPACT AND IMPLICATIONS: Steatotic liver disease (SLD) remains underdiagnosed in the general population. This study provides new population-based data on its prevalence and severity among individuals with metabolic and/or alcohol-related risk. These findings are relevant to clinicians, researchers, and public health planners, as prevalence data are essential to inform evolving screening strategies. Methodological limitations, including the cross-sectional design and limited generalizability, should be considered when interpreting the results. CLINICALTRIALS: GOV: NCT03308916.
引用
- Hansen CD, Hansen JK, Israelsen M, et al. Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community. J Hepatol. 2025. PMID: 40618958. doi:10.1016/j.jhep.2025.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。